breast cancer
Conditions
Interventions
two:CIK
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 77 Years
Inclusion criteria
Inclusion criteria: This study was a phase I, single institution trial. This study was approved by the Ethics Committee of the Peking University Cancer Hospital and written informed consents were obtained from all participants. Patients were eligible for this study if they had recurrent, symptomatic, cytologically proved MPE caused by breast cancer. And the patients failed with the prior intrapleural therapy which stopped at least four weeks before the trial entry. Other inclusion criteria included age = 18 years, Eastern Cooperative Oncology Group performance status (PS) of 0-2, predicted survival time = 3 months; adequate renal function (creatinine = 120 umol/L), adequate blood cell counts (neutrophil count = 1.5×10^9/L; platelet count = 100×10^9/L) and adequate hepatic function (total bilirubin = 1.5mg/dl and transaminase = twice the upper limit of the normal value).
Exclusion criteria
Exclusion criteria: Patients were excluded if they were allergic to cytokines IL-2 and GM-CSF. Patients could not be pregnant, lactating, symptomatic brain metastasis, or with a medical history of other malignancy except for those of cervical carcinoma in situ or skin-basal cell carcinoma who had been cured and without relapse in last 5 years. Patients with the history of uncontrolled diseases such as congestive heart failure and myocardial infarction within last 3 months, coronary heart disease, and arrhythmia were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| malignant pleural effusion ; | — |
Countries
China
Contacts
Public ContactShao Bin
Peking University Cancer Hospital
Outcome results
None listed